← Leaderboards
Xiao Xiao
University Of Pittsburgh At Pittsburgh
$14,631,158
Attributed
$14,631,158
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2005–17$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$14,631,158 · 10
By mechanism
R01$10,554,952 · 6
U54$1,874,707 · 2
U01$1,637,933 · 1
P01$563,566 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Stephen D Meriney$4,868,096
- Dong Moon Shin$11,702,631
- Xiangyun Wei$5,050,148
- John W Evankovich$2,454,887
- Albert E Chung$565,260
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyMuscleAdeno-Associated Viral VectorGene DeliveryGenesSafetyTreatment EfficacyAnimal ModelGene ExpressionPathologyLongevityVectorMuscular DystrophiesGene TransferMediatingMyopathyAnimalsTechnologySuccessToxic EffectHamstersGeneticSerotypingLead
Grant awards (49)
Gene delivery to muscle and nerve for laminin-alpha2-deficient MD (MDC1A)$332,500
R01 · FY2017 · NS · contact PI
Gene delivery for fukutin-related protein deficiencies.$335,662
R01 · FY2016 · NS · contact PI
Gene delivery to muscle and nerve for laminin-alpha2-deficient MD (MDC1A)$332,500
R01 · FY2016 · NS · contact PI
Gene delivery for fukutin-related protein deficiencies.$335,629
R01 · FY2015 · NS · contact PI
Gene delivery to muscle and nerve for laminin-alpha2-deficient MD (MDC1A)$332,500
R01 · FY2015 · NS · contact PI
Muscle as a Platform for Type 2 Diabetes Treatment by Gene Delivery$329,300
R01 · FY2015 · DK · contact PI
Gene delivery for fukutin-related protein deficiencies.$332,240
R01 · FY2014 · NS · contact PI
Muscle as a Platform for Type 2 Diabetes Treatment by Gene Delivery$329,300
R01 · FY2014 · DK · contact PI
Gene delivery to muscle and nerve for laminin-alpha2-deficient MD (MDC1A)$329,176
R01 · FY2014 · NS · contact PI
Gene delivery for fukutin-related protein deficiencies.$348,565
R01 · FY2013 · NS · contact PI
Gene delivery to muscle and nerve for laminin-alpha2-deficient MD (MDC1A)$332,500
R01 · FY2013 · NS · contact PI
Muscle as a Platform for Type 2 Diabetes Treatment by Gene Delivery$317,774
R01 · FY2013 · DK · contact PI
Myostatin Inhibition in DMD Dogs by Gene Transfer$300,659
R01 · FY2013 · AR · contact PI
Gene therapy in golden retriever muscular dystrophy model$344,147
U54 · FY2012 · AR · contact PI
Muscle as a Platform for Type 2 Diabetes Treatment by Gene Delivery$329,300
R01 · FY2012 · DK · contact PI
Myostatin Inhibition in DMD Dogs by Gene Transfer$316,483
R01 · FY2012 · AR · contact PI
Muscle as a Platform for Type 2 Diabetes Treatment by Gene Delivery$370,000
R01 · FY2011 · DK · contact PI
Gene therapy in golden retriever muscular dystrophy model$346,004
U54 · FY2011 · AR · contact PI
Myostatin Inhibition in DMD Dogs by Gene Transfer$316,483
R01 · FY2011 · AR · contact PI
Gene therapy in golden retriever muscular dystrophy model$347,812
U54 · FY2010 · AR · contact PI
Myostatin Inhibition in DMD Dogs by Gene Transfer$329,670
R01 · FY2010 · AR · contact PI
Gene therapy in golden retriever muscular dystrophy model$348,623
U54 · FY2009 · AR · contact PI
Myostatin Inhibition in DMD Dogs by Gene Transfer$333,000
R01 · FY2009 · AR · contact PI
Gene therapy in golden retriever muscular dystrophy model$349,687
U54 · FY2008 · AR · contact PI
AAV Vectors for Heart and Muscle Gene Therapy$302,982
R01 · FY2008 · AR · contact PI
Gene Therapy for a severe DMD Animal Model$297,689
R01 · FY2008 · AR · contact PI
Preclinical Gene Therapy in a Large Animal Model of DMD$4
U54 · FY2008 · AR · contact PI
AAV Mini-dystrophin Vectors for DMD Gene Therapy$456,992
U01 · FY2007 · NS · contact PI
AAV Vectors for Heart and Muscle Gene Therapy$309,166
R01 · FY2007 · AR · contact PI
Gene Therapy for a severe DMD Animal Model$304,827
R01 · FY2007 · AR · contact PI
Preclinical Gene Therapy in a Large Animal Model of DMD$138,430
U54 · FY2007 · AR · contact PI
AAV Mini-dystrophin Vectors for DMD Gene Therapy$475,599
U01 · FY2006 · NS · contact PI
AAV Vectors for Heart and Muscle Gene Therapy$318,400
R01 · FY2006 · AR · contact PI
Gene Therapy for a severe DMD Animal Model$294,411
R01 · FY2006 · AR · contact PI
Gene Therapy for a severe DMD Animal Model$24,758
R01 · FY2006 · AR · contact PI
AAV Mini-dystrophin Vectors for DMD Gene Therapy$346,889
U01 · FY2005 · NS
AAV Vectors for Heart and Muscle Gene Therapy$331,317
R01 · FY2005 · AR
Gene Therapy for a severe DMD Animal Model$327,494
R01 · FY2005 · AR
AAV Mini-dystrophin Vectors for DMD Gene Therapy$358,453
U01 · FY2004 · NS
Gene Therapy for a severe DMD Animal Model$340,471
R01 · FY2004 · AR
AAV Vectors for Heart and Muscle Gene Therapy$331,217
R01 · FY2004 · AR
AAV VECTORS FOR MUSCULAR DYSTROPHY (LGMD) GENE THERAPY$284,157
R01 · FY2003 · AR
Preclinical Gene Therapy in a Large Animal Model of DMD$0
U54 · FY2003 · AR
AAV VECTORS FOR MUSCULAR DYSTROPHY (LGMD) GENE THERAPY$275,880
R01 · FY2002 · AR
ADENO-ASSOCIATED VIRUS (AAV) VECTORS TO IMPROVE MATURE MUSCLE FUNCTION$196,218
P01 · FY2002 · AR
AAV VECTORS FOR MUSCULAR DYSTROPHY (LGMD) GENE THERAPY$268,061
R01 · FY2001 · AR
ADENO-ASSOCIATED VIRUS (AAV) VECTORS TO IMPROVE MATURE MUSCLE FUNCTION$196,218
P01 · FY2001 · AR
AAV VECTORS FOR MUSCULAR DYSTROPHY (LGMD) GENE THERAPY$260,881
R01 · FY2000 · AR
ADENO-ASSOCIATED VIRUS (AAV) VECTORS TO IMPROVE MATURE MUSCLE FUNCTION$171,130
P01 · FY2000 · AR